APA (7th ed.) Citation

MO, G., VM, S., AH, E., R, R., O, O., NHK, N., . . . JK, L. (2022). A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials. Leukemia, 36(8), 2022. https://doi.org/10.1038/s41375-022-01622-0

Chicago Style (17th ed.) Citation

MO, Gbadamosi, et al. "A Ten-gene DNA-damage Response Pathway Gene Expression Signature Predicts Gemtuzumab Ozogamicin Response in Pediatric AML Patients Treated on COGAAML0531 and AAML03P1 Trials." Leukemia 36, no. 8 (2022): 2022. https://doi.org/10.1038/s41375-022-01622-0.

MLA (9th ed.) Citation

MO, Gbadamosi, et al. "A Ten-gene DNA-damage Response Pathway Gene Expression Signature Predicts Gemtuzumab Ozogamicin Response in Pediatric AML Patients Treated on COGAAML0531 and AAML03P1 Trials." Leukemia, vol. 36, no. 8, 2022, p. 2022, https://doi.org/10.1038/s41375-022-01622-0.